| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $7.8M | 0.01% | 1.61M | −17% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ZNTL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Bruns IngmarOfficer | Stock Award(Grant) at price 2.77 per share. | 9.7K | $26.94K |
| Aug 13, 2026 | Walters GroupBeneficial Owner of more than 10% of a Class of Security | Purchase at price 3.50 per share. | 4.33M | $15.17M |
| Jun 15, 2026 | Myers Scott DunsethDirector | Stock Award(Grant) at price 0.00 per share. | 57.1K | — |
| Jun 15, 2026 | Walker Luke NathanielDirector | Stock Award(Grant) at price 0.00 per share. | 57.1K | — |
| Jun 15, 2026 | Johnson David MichaelDirector | Stock Award(Grant) at price 0.00 per share. | 57.1K | — |
| Jun 15, 2026 | Skvarka JanDirector | Stock Award(Grant) at price 0.00 per share. | 57.1K | — |
| Jun 15, 2026 | Kariuki EnochDirector | Stock Award(Grant) at price 0.00 per share. | 57.1K | — |
| May 25, 2026 | Campbell ShannonDirector | Stock Award(Grant) at price 0.00 per share. | 114.2K | — |
| Feb 9, 2026 | Vultaggio VincentOfficer | Sale at price 2.39 - 2.43 per share. | 40.2K | $97.56K |
| Feb 8, 2026 | Bruns IngmarOfficer | Sale at price 2.39 - 2.43 per share. | 3.3K | $8.00K |
| Feb 8, 2026 | Eastland Julia MarieChief Executive Officer | Sale at price 2.39 - 2.43 per share. | 8.8K | $21.24K |
| Feb 2, 2026 | Vultaggio VincentOfficer | Sale at price 2.52 - 2.55 per share. | 3.1K | $7.88K |
| Dec 30, 2025 | Walters GroupBeneficial Owner of more than 10% of a Class of Security | Purchase at price 1.20 per share. | 6.46M | $7.75M |
| Dec 14, 2025 | Matrix Capital Management Company, LpBeneficial Owner of more than 10% of a Class of Security | Sale at price 1.33 per share. | 7.50M | $9.97M |
| Jun 16, 2025 | Myers Scott DunsethDirector | Stock Award(Grant) at price 0.00 per share. | 57.6K | — |
| Jun 16, 2025 | Walker Luke NathanielDirector | Stock Award(Grant) at price 0.00 per share. | 57.6K | — |
| Jun 16, 2025 | Johnson David MichaelDirector | Stock Award(Grant) at price 0.00 per share. | 57.6K | — |
| Jun 16, 2025 | Skvarka JanDirector | Stock Award(Grant) at price 0.00 per share. | 57.6K | — |
| Jun 16, 2025 | Kariuki EnochDirector | Stock Award(Grant) at price 0.00 per share. | 57.6K | — |
| Apr 29, 2025 | Myers Scott DunsethDirector | Purchase at price 1.40 per share. | 21K | $29.37K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 80.0 | -1.6 | -2.1 | 71.4 | -0.2 | 21.2 | -2.3 | -20.7 | -26.3 | -13.4 | +77.8% | ||
| 2025 | -42.6 | 19.0 | -23.2 | -10.7 | -14.8 | -4.1 | 19.0 | 22.5 | -10.7 | -0.7 | -4.7 | -5.6 | −55.4% |
| 2024 | -21.8 | 25.8 | 5.7 | -29.8 | 7.4 | -65.6 | -4.9 | -10.8 | 6.1 | -25.8 | 32.2 | -16.1 | −80.0% |
| 2023 | 17.2 | -19.8 | -9.1 | 28.1 | 18.2 | 8.3 | -5.3 | -0.6 | -24.5 | -18.4 | -31.2 | 34.7 | −24.8% |
| 2022 | -32.1 | -12.6 | -7.5 | -42.5 | -9.1 | 16.5 | 3.9 | -8.2 | -19.2 | 15.8 | -11.8 | -9.0 | −76.0% |
| 2021 | -26.1 | 9.6 | 3.2 | 36.7 | -5.8 | -4.7 | 0.0 | 28.2 | -2.3 | 20.7 | 2.0 | 2.4 | +61.8% |
| 2020 | 48.8 | -8.0 | -28.2 | -0.3 | -5.0 | 21.1 | 28.7 | 1.9 | +48.0% |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Buy / hold / sell counts